BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36279135)

  • 21. Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: from the revised Bethesda guidelines to a universal approach.
    Morrison J; Bronner M; Leach BH; Downs-Kelly E; Goldblum JR; Liu X
    Scand J Gastroenterol; 2011 Nov; 46(11):1340-8. PubMed ID: 21879804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.
    Niessen RC; Berends MJ; Wu Y; Sijmons RH; Hollema H; Ligtenberg MJ; de Walle HE; de Vries EG; Karrenbeld A; Buys CH; van der Zee AG; Hofstra RM; Kleibeuker JH
    Gut; 2006 Dec; 55(12):1781-8. PubMed ID: 16636019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
    Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
    J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing.
    Zhang L
    J Mol Diagn; 2008 Jul; 10(4):301-7. PubMed ID: 18556776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic testing for hereditary nonpolyposis colorectal cancer.
    Hoedema R; Monroe T; Bos C; Palmer S; Kim D; Marvin M; Luchtefeld M
    Am Surg; 2003 May; 69(5):387-91; discussion 391-2. PubMed ID: 12769209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population-based screening for Lynch syndrome in Western Australia.
    Schofield L; Grieu F; Amanuel B; Carrello A; Spagnolo D; Kiraly C; Pachter N; Goldblatt J; Platell C; Levitt M; Stewart C; Salama P; Ee H; Raftopoulous S; Katris P; Threlfall T; Edkins E; Wallace M; Iacopetta B
    Int J Cancer; 2014 Sep; 135(5):1085-91. PubMed ID: 24474394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability.
    Kets CM; van Krieken JH; Hebeda KM; Wezenberg SJ; Goossens M; Brunner HG; Ligtenberg MJ; Hoogerbrugge N
    Br J Cancer; 2006 Dec; 95(12):1678-82. PubMed ID: 17117178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Universal Versus Age-Restricted Screening of Colorectal Tumors for Lynch Syndrome Using Mismatch Repair Immunohistochemistry: A Cohort Study.
    Li D; Hoodfar E; Jiang SF; Udaltsova N; Pham NP; Jodesty Y; Armstrong MA; Hung YY; Baker RJ; Postlethwaite D; Ladabaum U; Levin TR; Corley DA; Bergoffen J
    Ann Intern Med; 2019 Jul; 171(1):19-26. PubMed ID: 31181578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population-based molecular screening for Lynch syndrome: implications for personalized medicine.
    Ward RL; Hicks S; Hawkins NJ
    J Clin Oncol; 2013 Jul; 31(20):2554-62. PubMed ID: 23733757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications.
    Bonis PA; Trikalinos TA; Chung M; Chew P; Ip S; DeVine DA; Lau J
    Evid Rep Technol Assess (Full Rep); 2007 May; (150):1-180. PubMed ID: 17764220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.
    Batte BA; Bruegl AS; Daniels MS; Ring KL; Dempsey KM; Djordjevic B; Luthra R; Fellman BM; Lu KH; Broaddus RR
    Gynecol Oncol; 2014 Aug; 134(2):319-25. PubMed ID: 24933100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer.
    Bruegl AS; Ring KL; Daniels M; Fellman BM; Urbauer DL; Broaddus RR
    Cancer Prev Res (Phila); 2017 Feb; 10(2):108-115. PubMed ID: 27965287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.
    Alqahtani M; Edwards C; Buzzacott N; Carpenter K; Alsaleh K; Alsheikh A; Abozeed W; Mashhour M; Almousa A; Housawi Y; Al Hawwaj S; Iacopetta B
    Fam Cancer; 2018 Apr; 17(2):197-203. PubMed ID: 28643016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome.
    Gould-Suarez M; El-Serag HB; Musher B; Franco LM; Chen GJ
    Dig Dis Sci; 2014 Dec; 59(12):2913-26. PubMed ID: 24957400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer.
    Kastrinos F; Steyerberg EW; Balmaña J; Mercado R; Gallinger S; Haile R; Casey G; Hopper JL; LeMarchand L; Lindor NM; Newcomb PA; Thibodeau SN; Syngal S;
    Gut; 2013 Feb; 62(2):272-9. PubMed ID: 22345660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for Lynch Syndrome in Young Colorectal Cancer Patients from Saudi Arabia Using Microsatellite Instability as the Initial Test.
    Alqahtani M; Grieu F; Carrello A; Amanuel B; Mashour M; Alattas R; Alsaleh K; Alsheikh A; Alqahtani S; Iacopetta B
    Asian Pac J Cancer Prev; 2016; 17(4):1917-23. PubMed ID: 27221876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early-onset colorectal cancer patients without family history are "at very low risk" for lynch syndrome.
    Stigliano V; Sanchez-Mete L; Martayan A; Diodoro M; Casini B; Sperduti I; Anti M
    J Exp Clin Cancer Res; 2014 Jan; 33(1):1. PubMed ID: 24383517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel.
    Jiang W; Li L; Ke CF; Wang W; Xiao BY; Kong LH; Tang JH; Li Y; Wu XD; Hu Y; Guo WH; Wang SZ; Wan DS; Xu RH; Pan ZZ; Ding PR
    J Med Genet; 2022 Apr; 59(4):370-376. PubMed ID: 33563768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer.
    de Jong AE; van Puijenbroek M; Hendriks Y; Tops C; Wijnen J; Ausems MG; Meijers-Heijboer H; Wagner A; van Os TA; Bröcker-Vriends AH; Vasen HF; Morreau H
    Clin Cancer Res; 2004 Feb; 10(3):972-80. PubMed ID: 14871975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.